$2.86
1.75%
Downside
Day's Volatility :8.02%
Upside
6.38%
47.2%
Downside
52 Weeks Volatility :56.23%
Upside
17.1%
Period | Erasca Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 20.42% | 5.1% | 0.0% |
6 Months | 33.02% | 4.9% | 0.0% |
1 Year | 9.58% | 16.6% | 0.0% |
3 Years | -87.42% | 13.2% | -22.3% |
Market Capitalization | 808.0M |
Book Value | $1.65 |
Earnings Per Share (EPS) | -0.93 |
Wall Street Target Price | 4.57 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.14% |
Return On Equity TTM | -38.9% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -143.9M |
Diluted Eps TTM | -0.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.86 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.18 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Upside of 59.79%
Sell
Neutral
Buy
Erasca Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Erasca Inc. | 18.67% | 33.02% | 9.58% | -87.42% | -83.59% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Erasca Inc. | NA | NA | NA | -0.86 | -0.39 | -0.19 | NA | 1.65 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Erasca Inc. | Buy | $808.0M | -83.59% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Erasca Inc.
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 27.5%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 156.6%
VR Adviser, LLC
Suvretta Capital Management, LLC
ARCH VENTURE CORP
BlackRock Inc
Vanguard Group Inc
Artal Group S A
our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.
Organization | Erasca Inc. |
Employees | 126 |
CEO | Dr. Jonathan E. Lim M.D. |
Industry | Services |
Telecom Argentina S.a.
$2.86
-4.35%
Jianzhi Education Technology Group Company Ltd.
$2.86
-4.35%
Regis Corp
$2.86
-4.35%
Gladstone Land Corporation
$2.86
-4.35%
Papa John's International Inc.
$2.86
-4.35%
Sunlands Online Education Group
$2.86
-4.35%
Gigacloud Technology Inc
$2.86
-4.35%
Noodles & Co
$2.86
-4.35%
Madison Square Garden Entertainment Corp
$2.86
-4.35%